These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 35470308)
1. Comparison of the Pharmacokinetics of CT-P13 Between Crohn's Disease and Ulcerative Colitis. Kim ES; Kim SK; Park DI; Kim HJ; Lee YJ; Koo JS; Kim ES; Yoon H; Lee JH; Kim JW; Shin SJ; Kim HW; Kim HS; Park YS; Kim YS; Kim TO; Lee J; Choi CH; Han DS; Chun J; Kim HS; J Clin Gastroenterol; 2023 Jul; 57(6):601-609. PubMed ID: 35470308 [TBL] [Abstract][Full Text] [Related]
2. Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center. Farkas K; Rutka M; Ferenci T; Nagy F; Bálint A; Bor R; Milassin Á; Fábián A; Szántó K; Végh Z; Kürti Z; Lakatos PL; Szepes Z; Molnár T Expert Opin Biol Ther; 2017 Nov; 17(11):1325-1332. PubMed ID: 28819991 [TBL] [Abstract][Full Text] [Related]
3. Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role? Gonczi L; Vegh Z; Golovics PA; Rutka M; Gecse KB; Bor R; Farkas K; Szamosi T; Bene L; Gasztonyi B; Kristóf T; Lakatos L; Miheller P; Palatka K; Papp M; Patai Á; Salamon Á; Tóth GT; Vincze Á; Biro E; Lovasz BD; Kurti Z; Szepes Z; Molnár T; Lakatos PL J Crohns Colitis; 2017 Jun; 11(6):697-705. PubMed ID: 27838610 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis - experiences from a single center. Farkas K; Rutka M; Bálint A; Nagy F; Bor R; Milassin Á; Szepes Z; Molnár T Expert Opin Biol Ther; 2015; 15(9):1257-62. PubMed ID: 26134250 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study. Smith PJ; Critchley L; Storey D; Gregg B; Stenson J; Kneebone A; Rimmer T; Burke S; Hussain S; Yi Teoh W; Vazeille S; Serna S; Steel A; Derbyshire E; Collins P; Dibb M; Flanagan P; Probert C; Verma AM; Subramanian S J Crohns Colitis; 2022 Sep; 16(9):1436-1446. PubMed ID: 35390141 [TBL] [Abstract][Full Text] [Related]
6. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study. Smits LJ; Derikx LA; de Jong DJ; Boshuizen RS; van Esch AA; Drenth JP; Hoentjen F J Crohns Colitis; 2016 Nov; 10(11):1287-1293. PubMed ID: 27095751 [TBL] [Abstract][Full Text] [Related]
7. Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade. Ilias A; Szanto K; Gonczi L; Kurti Z; Golovics PA; Farkas K; Schafer E; Szepes Z; Szalay B; Vincze A; Szamosi T; Molnar T; Lakatos PL Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2506-2513.e2. PubMed ID: 30630103 [TBL] [Abstract][Full Text] [Related]
8. Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY). Hanauer SB; Sands BE; Schreiber S; Danese S; Kłopocka M; Kierkuś J; Kulynych R; Gonciarz M; Sołtysiak A; Smoliński P; Srećković S; Valuyskikh E; Lahat A; Horyński M; Gasbarrini A; Osipenko M; Borzan V; Kowalski M; Saenko D; Sardinov R; Lee SJ; Kim S; Bae Y; Lee S; Lee S; Lee JH; Yang S; Lee J; Lee J; Kim JM; Park G; Sandborn WJ; Colombel JF Gastroenterology; 2024 Oct; 167(5):919-933. PubMed ID: 38788861 [TBL] [Abstract][Full Text] [Related]
9. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial. Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR; Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564 [TBL] [Abstract][Full Text] [Related]
10. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study. Jahnsen J; Detlie TE; Vatn S; Ricanek P Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534 [TBL] [Abstract][Full Text] [Related]
11. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis. Keil R; Wasserbauer M; Zádorová Z; Hajer J; Drastich P; Wohl P; Beneš M; Bojková M; Svoboda P; Konečný M; Falt P; Vaňásek T; Pešta M; Pešek F; Bouchner L; Koželuhová J; Novotný A; Bartůsková L; Špičák J Scand J Gastroenterol; 2016 Sep; 51(9):1062-8. PubMed ID: 27002981 [TBL] [Abstract][Full Text] [Related]
12. Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients. Eberl A; Huoponen S; Pahikkala T; Blom M; Arkkila P; Sipponen T Scand J Gastroenterol; 2017 Dec; 52(12):1348-1353. PubMed ID: 28838273 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis. Farkas K; Rutka M; Golovics PA; Végh Z; Lovász BD; Nyári T; Gecse KB; Kolar M; Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Malickova K; Bálint A; Nagy F; Bor R; Milassin Á; Szepes Z; Palatka K; Lakatos PL; Lukas M; Molnár T J Crohns Colitis; 2016 Nov; 10(11):1273-1278. PubMed ID: 27106537 [TBL] [Abstract][Full Text] [Related]
15. Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study. Barberio B; Zingone F; D'Incà R; Rovigo L; Bertani L; Bodini G; Ghisa M; Gubbiotti A; Massimi D; Lorenzon G; Savarino EV Clin Transl Gastroenterol; 2020 May; 11(5):e00177. PubMed ID: 32677808 [TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study. Kim NH; Lee JH; Hong SN; Yoon H; Kang HW; Lee SH; Im JP; Cha JM; Eun CS; Kim JW; Choi CH; Park DI J Gastroenterol Hepatol; 2019 Sep; 34(9):1523-1532. PubMed ID: 30828891 [TBL] [Abstract][Full Text] [Related]
17. Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment. Krajcovicova A; Batovsky M; Gregus M; Hlista M; Durina J; Leskova Z; Sturdik I; Gojdic M; Jalali Y; Koller T; Toth J; Huorka M; Hlavaty T Acta Gastroenterol Belg; 2018; 81(4):465-470. PubMed ID: 30645913 [TBL] [Abstract][Full Text] [Related]
18. Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort. Gonczi L; Gecse KB; Vegh Z; Kurti Z; Rutka M; Farkas K; Golovics PA; Lovasz BD; Banai J; Bene L; Gasztonyi B; Kristof T; Lakatos L; Miheller P; Nagy F; Palatka K; Papp M; Patai A; Salamon A; Szamosi T; Szepes Z; Toth GT; Vincze A; Szalay B; Molnar T; Lakatos PL Inflamm Bowel Dis; 2017 Nov; 23(11):1908-1915. PubMed ID: 28922253 [TBL] [Abstract][Full Text] [Related]
19. Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn's Disease Comparing, between CT-P13 and Originator Infliximab. Park J; Cheon JH; Lee KM; Kim YH; Ye BD; Eun CS; Kim SH; Lee SH; Lee JH; Schreiber S Gut Liver; 2023 May; 17(3):430-440. PubMed ID: 35975641 [TBL] [Abstract][Full Text] [Related]
20. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Park SH; Kim YH; Lee JH; Kwon HJ; Lee SH; Park DI; Kim HK; Cheon JH; Im JP; Kim YS; Lee SY; Lee SJ Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():35-44. PubMed ID: 26395533 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]